Drug salts and solubilization: Modeling the influence of cyclodextrins on oral absorption

Annals of Biomedical Engineering

Volumn 39, Issue 1, 2011, Pages 455-468

  Gamsiz, Ece Dilber ^a,b   Thombre, Avinash G ^c   Ahmed, Imran ^c   Carrier, Rebecca Lyn ^a  

^a Northeastern University   (United States)

^b BROWN UNIVERSITY   (United States)

^c PFIZER INC   (United States)

Author keywords

Complexation; Drug delivery; Mathematical modeling; Saltforms

Indexed keywords

CDS; DISSOLUTION KINETICS; DRIVING FORCES; DRUG ABSORPTION; DRUG DISSOLUTION; FORMULATION PROCESS; IN-VITRO; MATHEMATICAL MODELING; MODEL PREDICTION; ORAL ABSORPTION; ORAL DELIVERY; PHYSICAL AND CHEMICAL PROPERTIES; PHYSICAL MIXTURES; SALTFORMS; SIMULTANEOUS USE;

ABSORPTION; COMPUTER SIMULATION; CYCLODEXTRINS; DISSOLUTION; DRUG DELIVERY; DRUG PRODUCTS; PRECIPITATION (CHEMICAL); SOLUBILITY; TECHNOLOGY;

MODELS;

CYCLODEXTRIN; DRUG CARRIER; INORGANIC SALT;

ABSORPTION; ANIMAL; ARTICLE; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DIFFUSION; DRUG FORMULATION; HUMAN; INTESTINE; INTESTINE ABSORPTION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SOLUBILITY;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; CYCLODEXTRINS; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MODELS, BIOLOGICAL; MODELS, CHEMICAL; SALTS; SOLUBILITY;

EID: 78650900635     PISSN: 00906964     EISSN: 15739686     Source Type: Journal    
DOI: 10.1007/s10439-010-0169-1     Document Type: Article

References (31)

1. H Arima F Hirayama CT Okamoto K Uekama 2002 Recent aspects of cyclodextrin-based pharmaceutical formulations Recent Res. Dev. Chem. Pharm. Sci. 2 155 193 1:CAS:528:DC%2BD3sXoslKitbg%3D
2. SM Berge LD Bighley DC Monkhouse 1977 Pharmaceutical salts J. Pharm. Sci. 66 1 19 1:CAS:528:DyaE2sXmtVCnsw%3D%3D 10.1002/jps.2600660104 833720 (Pubitemid 8022879)
3. KS Cameron L Fielding 2002 NMR diffusion coefficient study of steroid-cyclodextrin inclusion complexes Magn. Reson. Chem. 40 S106 S109 1:CAS:528:DC%2BD38XpsVOiu74%3D 10.1002/mrc.1083 (Pubitemid 37296920)
4. RL Carrier LA Miller I Ahmed 2007 The utility of cyclodextrins for enhancing oral bioavailability J. Control. Release 123 78 99 1:CAS:528:DC%2BD2sXhtFyku7fI 10.1016/j.jconrel.2007.07.018 17888540 (Pubitemid 47566400)
5. R Challa A Ahuja J Ali RK Khar 2005 Cyclodextrins in drug delivery: an updated review AAPS PharmSciTech 6 E329 E357 10.1208/pt060243 16353992 (Pubitemid 41631739)
6. A Dahan JM Miller A Hoffman GE Amidon GL Amidon 2010 The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone J. Pharm. Sci. 99 2739 2749 1:CAS:528:DC%2BC3cXkvVOktrc%3D 20039391
7. JB Dressman GL Amidon D Fleisher 1985 Absorption potential: estimating the fraction absorbed for orally administered compounds J. Pharm. Sci. 74 588 589 1:CAS:528:DyaL2MXktFKgur0%3D 10.1002/jps.2600740523 4020642
8. JB Dressman D Fleisher 1986 Mixing-tank model for predicting dissolution rate control or oral absorption J. Pharm. Sci. 75 109 116 1:CAS:528: DyaL28XhslCmsro%3D 10.1002/jps.2600750202 3958917 (Pubitemid 16162530)
9. ED Gamsiz L Miller AG Thombre I Ahmed RL Carrier 2010 Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development Biotechnol. Bioeng. 105 409 420 1:CAS:528:DC%2BD1MXhs1Sru7zP 10.1002/bit.22523 19725042
10. ED Gamsiz L Miller AG Thombre I Ahmed RL Carrier 2010 Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation Biotechnol. Bioeng. 105 421 430 1:CAS:528: DC%2BD1MXhs1Sru7zI 10.1002/bit.22524 19725043
11. WE Hamlin WI Higuchi 1966 Dissolution rate-solubility behavior of 3-(1-methyl-2-pyrrolidinyl)-indole as a function of hydrogen-ion concentration J. Pharm. Sci. 55 205 207 1:CAS:528:DyaF28XltFajsg%3D%3D 10.1002/jps.2600550216 5923271
12. T Higuchi KA Connors 1965 Phase solubility diagram Adv. Anal. Chem. Instrum. 4 117 212 1:CAS:528:DyaF2MXktlGitrg%3D
13. P Jansook T Loftsson 2009 CDs as solubilizers: effects of excipients and competing drugs Int. J. Pharm. 379 32 40 1:CAS:528:DC%2BD1MXhtVaqs7vF 10.1016/j.ijpharm.2009.06.005 19524652
14. Y Kim DA Oksanen W Massefski Jr JF Blake EM Duffy B Chrunyk 1998 Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether J. Pharm. Sci. 87 1560 1567 1:CAS:528:DyaK1cXmt1yhsbs%3D 10.1021/js980109t 10189267 (Pubitemid 28559642)
15. 3 concentrations as factors in the etiology of experimental amebiasis Am. J. Trop. Med. Hyg. 38 480 486 1:CAS:528:DyaL1cXkvFSmur4%3D 2908580
16. J Li PW Carr 1997 Accuracy of empirical correlations for estimating diffusion coefficients in aqueous organic mixtures Anal. Chem. 69 2530 2536 1:CAS:528:DyaK2sXjsFSmu70%3D 10.1021/ac961005a 9212712
17. S Li S Wong S Sethia H Almoazen YM Joshi AT Serajuddin 2005 Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH Pharm. Res. 22 628 635 1:CAS:528:DC%2BD2MXjsFahtbY%3D 10.1007/s11095-005-2504-z 15846471 (Pubitemid 40603261)
18. T Loftsson ME Brewster 1996 Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1017 1025 1:CAS:528:DyaK28XlsFSrsr4%3D 10.1021/js950534b 8897265 (Pubitemid 26338912)
19. T Loftsson ME Brewster M Masson 2004 Role of cyclodextrins in improving oral drug delivery Am. J. Drug Deliv. 2 261 275 1:CAS:528:DC%2BD2MXht12lurjL 10.2165/00137696-200402040-00006 (Pubitemid 40045491)
20. T Loftsson F Konradsdottir M Masson 2006 Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes Pharmazie 61 83 89 1:CAS:528:DC%2BD28XhvVGqtro%3D 16526552
21. T Loftsson SB Vogensen ME Brewster F Konradsdottir 2007 Effects of cyclodextrins on drug delivery through biological membranes J. Pharm. Sci. 96 2532 2546 1:CAS:528:DC%2BD2sXhtFKrtLnJ 10.1002/jps.20992 17630644 (Pubitemid 47597809)
22. AT Lu ME Frisella KC Johnson 1993 Dissolution modeling: factors affecting the dissolution rates of polydisperse powders Pharm. Res. 10 1308 1314 1:CAS:528:DyaK3sXmtleqsLk%3D 10.1023/A:1018917729477 8234168 (Pubitemid 23261831)
23. M Messner SV Kurkov P Jansook T Loftsson 2010 Self-assembled cyclodextrin aggregates and nanoparticles Int. J. Pharm. 387 199 208 1:CAS:528: DC%2BC3cXhs1Whsb4%3D 10.1016/j.ijpharm.2009.11.035 19963052
24. M Mizumori M Ham PH Guth E Engel JD Kaunitz Y Akiba 2009 Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum J. Physiol. 587 3651 3663 1:CAS:528:DC%2BD1MXpt1WrsLY%3D 10.1113/jphysiol.2009.172270 19451200
25. RA Rajewski VJ Stella 1996 Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery J. Pharm. Sci. 85 1142 1169 1:CAS:528: DyaK28XmtFKgu70%3D 10.1021/js960075u 8923319 (Pubitemid 26372882)
26. VM Rao VJ Stella 2003 When can cyclodextrins be considered for solubilization purposes? J. Pharm. Sci. 92 927 932 1:CAS:528: DC%2BD3sXjs1ehsr4%3D 10.1002/jps.10341 12712411 (Pubitemid 36523437)
27. VJ Stella RA Rajewski 1997 Cyclodextrins: their future in drug formulation and delivery Pharm. Res. 14 556 567 1:CAS:528:DyaK2sXjtlSksrg%3D 10.1023/A:1012136608249 9165524 (Pubitemid 27220271)
28. D Thompson 1997 Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals Crit. Rev. Ther. Drug Carr. Syst. 14 1 104 1:CAS:528:DyaK2sXhtlems7g%3D
29. K Uekama 2004 Design and evaluation of cyclodextrin-based drug formulation Chem. Pharm. Bull. 52 900 915 1:CAS:528:DC%2BD2cXmvVKktbg%3D 10.1248/cpb.52.900 15304981 (Pubitemid 41701863)
30. LX Yu 1999 An integrated model for determining causes of poor oral drug absorption Pharm. Res. 16 1883 1887 1:CAS:528:DC%2BD3cXkt1entg%3D%3D 10.1023/A:1018911728161 10644078
31. LX Yu GL Amidon 1999 A compartmental absorption and transit model for estimating oral drug absorption Int. J. Pharm. 186 119 125 1:CAS:528: DyaK1MXlvVWmtbg%3D 10.1016/S0378-5173(99)00147-7 10486429 (Pubitemid 29459038)